ArriVent announces PoC global Phase 1b interim data for firmonertinib

ArriVent BioPharma announced proof-of-concept randomized global Phase 1b FURTHER interim data for first-line firmonertinib monotherapy in patients with non-small cell lung cancer harboring EGFR PACC mutations at a Presidential Symposium Presentation at the IASCLC 2024 annual World Conference on Lung Cancer, in San Diego, California. ArriVent plans to host a virtual webinar on September 9, 2024 at 4:30 pm ET. Current standards of care have improved outcomes for classical EGFR mutations but have been less effective against uncommon EGFR mutation types including PACC and Exon 20 insertion mutations which represent approximately 12% and 9% of NSCLC EGFR mutations, respectively. Firmonertinib, an oral, once-daily, highly brain-penetrant EGFR inhibitor with broad activity across EGFR mutations, was evaluated for interim clinical proof-of-concept data in first-line EGFR PACC mutant NSCLC as part of the Phase 1b FURTHER trial. Select clinical activity and safety results from FURTHER interim data analysis include: First clinical dataset from an EGFR inhibitor being tested in a randomized defined population of EGFR PACC mutant NSCLC; Robust systemic and central nervous system responses across patients observed as of June 20, 2024: 81.8% at 240mg and 47.8% at 160mg overall response rate by blinded independent central review; 63.6% and 34.8% confirmed ORR by BICR at 240mg and 160mg dose levels, respectively. One unconfirmed partial response pending confirmation at each of the 160mg and 240mg dose levels. Median duration of response had not yet been reached; 90.9% patients with confirmed responses remain on study; 46.2% CNS confirmed ORR by modified; Response Evaluation Criteria in Solid Tumors 1.1 by BICR in first-line patients with brain metastases at baseline; Generally well-tolerated with a profile consistent with prior firmonertinib data; Most frequent treatment-related adverse events were diarrhea, rash, dry skin, stomatitis, and hepatic enzyme elevation; No treatment discontinuation due to TRAEs was observed; Firmonertinib showed promising dose-dependent activity in NSCLC patients across a broad range of EGFR PACC mutations in the first-line metastatic setting and includes CNS antitumor activity consistent with its high brain penetrance.